- Conditions
- Hypertension, Pulmonary
- Interventions
- Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Recruitment Status
Active, not recruiting clinical trials
Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
10537
Shown on this page
12
Current sort
Recently updated
Status scope
Active, not recruiting
Additional filters apply within this recruitment status.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 817–828 of 10,537 matching trials with status Active, not recruiting.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Multiple Myeloma
- Interventions
- Cevostamab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Baltimore, Maryland + 5 more
- Conditions
- Atrial Fibrillation
- Interventions
- Milvexian, Apixaban, Placebo, Apixaban Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20,284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 216
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Dothan, Alabama + 182 more
- Conditions
- Castration-Resistant Prostatic Cancer
- Interventions
- Niraparib, Abiraterone Acetate, Prednisone, Placebo, New Formulation of Niraparib and Abiraterone Acetate (AA)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 765 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 47
- States / cities
- Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 40 more
- Conditions
- Visual Acuity
- Interventions
- Test (Senofilcon A), Control (Serafilcon A)
- Device
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Industry
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Franklin Park, Illinois • Camden, New York + 5 more
- Conditions
- Respiratory Tract Diseases, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Neoplasms, Squamous Cell, Tumor Virus Infections, Infections, Virus Diseases, DNA Virus Infections, Pathologic Processes, Disease Attributes, Recurrence, Papilloma, Respiratory Tract Infections, Papillomavirus Infections
- Interventions
- Bevacizumab
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Amyloidosis
- Interventions
- Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 16
- States / cities
- Duarte, California • New Haven, Connecticut • Tampa, Florida + 12 more
- Conditions
- Liver Cancer
- Interventions
- CT guided percutaneous ablation
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Lazertinib, Amivantamab, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 701 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 12 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Clinical Observation, Echocardiography Test, Nivolumab
- Procedure · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Duarte, California + 34 more
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD
- Interventions
- Ensifentrine, Placebo, LABA/LAMA
- Drug
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Ann Arbor, Michigan • Pittsburgh, Pennsylvania
- Conditions
- Prostatic Neoplasms
- Interventions
- Niraparib, Abiraterone Acetate (AA), Prednisone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- West Valley City, Utah